MedPath

Gastrointestinal behavior of posaconazol in healthy human volunteers

Phase 1
Conditions
Suspension: 105 mg posaconazol (2.6 ml Noxafil): 1)with 250 ml water 2)with 250 ml sparkling water 3)with 5 lumps of sugar, dissolved in 250 ml water 3)with 5 lumps of sugar, dissolved in 250 ml of sparkling water. Solution: 105 mg dissolved posaconazol (via Noxafil) by acidification of HCl until pH 1.2: 1)with 250 ml water 2)with 250 ml sparkling water 3)with 5 lumps of sugar, dissolved in 250 ml water 3)with 5 lumps of sugar, dissolved in 250 ml of sparkling water.
Therapeutic area: Body processes [G] - Physiological processes [G07]
Registration Number
EUCTR2013-002836-26-BE
Lead Sponsor
KU Leuven - Drug Delivery & Disposition
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

-Healthy volunteers
-age between 18 and 40 years old
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-pregnancy
-disease
-use of medication

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Study of the gastrointestinal behavior of posaconazol in healthy volunteers by using a suspension of the drug and a solution. This will learn us more about the behaviour of the drug in the GI tract (supersaturation/ precipitation/ dissolution/ ...);<br> Secondary Objective: 1)To see any difference between administration of a suspension of the drug versus a solution (differences to supersaturation potential, precipitation potential and absorption potential)<br> 2)To see any difference of supersaturation, precipitation or absorption between the 2 formulations, when there is another time of gastric emptying (induced by the lumps of sugar/ sparkling water)<br> ;Primary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable
© Copyright 2025. All Rights Reserved by MedPath